Personalis Reports 30% Revenue Growth to $22.4 Million in Q2 2026 Amid Increased Losses

Personalis, Inc. reported a total revenue of $22.4 million for the second quarter of 2026, marking a 30% increase from $17.2 million in the same period last year. The growth was primarily driven by higher revenue from pharmaceutical testing services and clinical diagnostics, bolstered by recent Medicare reimbursement approvals for various cancer monitoring tests. However, the company also experienced a decline in enterprise sales due to the completion of a project with Natera and a planned reduction in population sequencing revenue from the U.S. Department of Veterans Affairs' Million Veteran Program.

In terms of profitability, Personalis recorded a net loss of $31.7 million for the second quarter, compared to a loss of $20.1 million in the prior year. The increase in losses was attributed to rising costs across various operational areas, including a 42% increase in the cost of revenue, which reached $17.6 million. Research and development expenses also rose by 32% to $16.3 million, reflecting increased personnel costs and lab activities aimed at enhancing clinical evidence for their offerings. Selling, general, and administrative expenses surged by 55% to $22.0 million, driven by higher marketing and personnel costs associated with the growth of their clinical diagnostic services.

Operationally, Personalis has been focusing on expanding its customer base and enhancing its service offerings. The company has secured significant Medicare coverage for its NeXT Personal® tests, which are used for monitoring treatment responses in various cancer types. As of June 30, 2026, the company had cash and cash equivalents totaling $94.0 million, alongside short-term investments of $118.7 million, providing a solid liquidity position to support ongoing operations and strategic initiatives.

Looking ahead, Personalis is navigating a pivotal period as it has entered into a merger agreement with Tempus AI, Inc. The merger, announced on July 20, 2026, is expected to enhance the company's market position and operational capabilities. However, the completion of the merger is subject to various conditions, including regulatory approvals and shareholder votes. The company anticipates that the merger will facilitate further growth and expansion in the precision oncology market, although it also acknowledges the potential risks associated with the transaction and the competitive landscape in which it operates.